
A Discounted Cash Flow model estimates what a business could be worth by projecting its future cash flows and then discounting those back into today’s dollars. It is essentially asking what a stream of future cash in your pocket is worth right now.
For Tenet Healthcare, the latest twelve month Free Cash Flow is about $2.62b. Using a 2 Stage Free Cash Flow to Equity model, analyst estimates are used where available and then Simply Wall St extrapolates further out. For example, Free Cash Flow for 2026 is projected at $2.64b and for 2027 at $2.49b, with further annual projections out to 2035, all in $. These projected cash flows are discounted back to today to arrive at an estimated intrinsic value per share of about $627.95.
Compared with the current share price of around $192.99, this DCF output suggests the shares trade at a 69.3% discount to that intrinsic value. On this model alone, Tenet Healthcare is assessed as significantly undervalued.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Tenet Healthcare is undervalued by 69.3%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.
For profitable companies, the P/E ratio is a useful shorthand because it links what you pay for each share directly to the earnings that business is currently generating. It helps you see how many dollars of price the market is assigning to each dollar of earnings.
What counts as a normal or fair P/E usually reflects what investors think about a company’s growth prospects and risk. Higher expected growth and lower perceived risk tend to justify a higher P/E, while slower growth or higher risk often go with a lower P/E.
Tenet Healthcare’s current P/E is 11.93x, compared with a Healthcare industry average of about 22.39x and a peer group average of 22.06x. Simply Wall St also calculates a proprietary Fair Ratio of 21.44x for Tenet Healthcare. This Fair Ratio represents the P/E you might expect given factors such as earnings growth, industry, profit margin, market cap and company specific risks.
Because the Fair Ratio adjusts for those fundamentals, it is a more tailored guide than a simple comparison with peers or the broad industry. With Tenet Healthcare trading on 11.93x versus a Fair Ratio of 21.44x, the shares are assessed as undervalued on this measure.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.
Earlier it was mentioned that there is an even better way to think about valuation, and on Simply Wall St that is done through Narratives, where you set out your story for Tenet Healthcare, link it to a forecast for revenue, earnings and margins, and end up with a Fair Value that you can compare directly to the current share price.
A Narrative is essentially your investment story written into numbers. Instead of only looking at a DCF or P/E screen, you describe how you think Tenet’s outpatient shift, behavioral health exposure, capital returns or policy risks play out, and the platform translates that view into a financial forecast and a Fair Value per share.
These Narratives live on the Tenet Healthcare Community page, are easy to use, and update automatically when new data, news or earnings are added. This allows you to see in real time how the implied Fair Value moves relative to today’s price and decide whether that gap looks wide enough to consider buying, holding or selling.
For example, one investor might build a more optimistic Tenet Healthcare Narrative that lines up with a Fair Value around US$288.00, while another might prefer a cautious view closer to US$228.45. By seeing both side by side with the current price you can quickly judge which story feels more realistic to you.
Do you think there's more to the story for Tenet Healthcare? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com